ADKEI said march-in rights appear to be weakened in the “other transaction authority” agreements it reviewed between the Biomedical Advanced Research and Development Authority (BARDA) and drug companies Johnson & Johnson, Roche and Regeneron. Regeneron has contracts worth up to $130 million to develop two therapies for the disease. Roche’s Genentech subsidiary has contracts worth $47 million to develop a pair of therapies. ADKEI said it also obtained agreements BARDA has with Moderna and Sanofi and found those contracts do contain Bayh-Dole taxpayer safeguards. The Washington Post reported last year that use of “other contracting authority” agreements has jumped in defense contracting under the Trump administration.

Source: Washington Post July 01, 2020 19:53 UTC